Anne Paulien van Wijngaarden (Anne P van Wijngaarden, Anne P van Wijngarden)

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 5

Top Topics

Immune Response

Tyrosine Kinase

Top Venues

Journal for immunotherapy of cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Isabel Britsch, Anne Paulien van Wijngaarden, Xiurong Ke, Mark Alexander Johannes Martinus Hendriks, Douwe Freerk Samplonius, Emily Maria Ploeg, Wijnand Helfrich
Novel Fab-peptide-HLA-I fusion proteins for redirecting pre-existing anti-CMV T cell immunity to selective eliminate carcinoma cells. Oncoimmunology 12 (1) (2023)
Isabel Britsch, Anne Paulien van Wijngaarden, Wijnand Helfrich
Applications of Anti-Cytomegalovirus T Cells for Cancer (Immuno)Therapy. Cancers 15 (15) (2023)
Emily Maria Ploeg, Douwe Freerk Samplonius, Xiao Xiong, Xiurong Ke, Mark Alexander Johannes Martinus Hendriks, Isabel Britsch, Anne Paulien van Wijngaarden, Hao Zhang, Wijnand Helfrich
Bispecific antibody CD73xEGFR more selectively inhibits the CD73/adenosine immune checkpoint on cancer cells and concurrently counteracts pro-oncogenic activities of CD73 and EGFR. Journal for immunotherapy of cancer 11 (9) (2023)
Isabel Britsch, Anne Paulien van Wijngaarden, Xiurong Ke, Mark Alexander Johannes Martinus Hendriks, Douwe Freerk Samplonius, Emily Maria Ploeg, Wijnand Helfrich
Novel Fab-peptide-HLA-I fusion proteins for redirecting pre-existing anti-CMV T cell immunity to selective eliminate carcinoma cells. Oncoimmunology 12 (1) (2023)
Mark Alexander Johannes Martinus Hendriks, Isabel Britsch, Xiurong Ke, Anne Paulien van Wijngaarden, Douwe Freerk Samplonius, Emily Maria Ploeg, Wijnand Helfrich
Cancer cells under immune attack acquire CD47-mediated adaptive immune resistance independent of the myeloid CD47-SIRPα axis. Oncoimmunology 10 (1) (2021)